G

GSK

Develops medicines, vaccines, and consumer health

ServiceNow Risk & Security Technical Product Owner

Full-TimePosted on 10/19/2026Deadline 11/1/26
No salary listed
Mid
Bachelor's, Master's
London, UK
HybridAt least 2–3 days per week on-site at the central London headquarters; fully remote work is unavailable.
IT OperationsEnterprise Applications

About the job

Requirements
  • A bachelor's or master's degree in a relevant field such as Computer Science, Information Technology, or Engineering, or equivalent experience.
  • Experience working in product delivery, digital solutions, business systems, or process-led technology roles.
  • Experience defining and prioritising functional requirements, such as epics, features, and user stories, and managing a product backlog.
  • Experience working within enterprise HR technology, service management, corporate systems, legal and compliance, or similar areas.
  • Experience working directly with business stakeholders to translate needs into feasible, value-led technology changes.
  • Ability to make prioritisation decisions based on business value, process impact, risk, cost, and technology constraints.
  • Experience leading delivery teams or analysts through the product lifecycle, from refinement and design through testing, release, and adoption.
  • Familiarity with enterprise governance requirements, including change control, security, data protection, and regulatory or compliance considerations.
  • Experience with continuous improvement approaches such as automation, process simplification, and user-centred enhancements to improve product adoption, stability, or user experience.
  • Experience working within agile delivery environments and using iterative planning, delivery, and release practices.
  • Strong communication and influencing skills to explain technology constraints and help stakeholders make informed product decisions.
  • Ability to coach and guide Product Analysts and delivery team members so requirements, documentation, and solutions meet business needs and compliance expectations.
  • Ability to interpret business processes, user feedback, and operational data to identify opportunities for process simplification, automation, and improved user experience.
  • Comfort working within structured governance, security, and data protection requirements to ensure product changes remain controlled, supportable, and compliant.
  • Ability to assess value, risk, complexity, and cost to prioritise and sequence backlog items.
Responsibilities
  • Partner with business stakeholders to understand functional needs, refine requirements, and define product outcomes that support business priorities within the guardrails set by the ServiceNow Business Service, Risk & Security Product Manager and the Senior Director of ServiceNow Platform & Enterprise Tools.
  • Own and manage the Product backlog, ensuring requirements such as epics, features, and user stories are well-defined, technically validated, and supported by minimum data inputs including cost drivers, user volumes, risk or sensitivity, process impact, and dependencies.
  • Prioritise the Product backlog based on value, cost, risk, business continuity, and resource capacity, applying technical judgement on implementation feasibility, configuration complexity, and ServiceNow platform constraints, and escalating strategic trade-offs when required.
  • Lead the Product team's delivery activities, guiding Product Analysts and working with Engineers, Architects, and Testers to ensure solutions are fit for purpose, secure, compliant, supportable, and aligned to architectural standards.
  • Own technical solution design for ServiceNow Risk & Security features, including configuration of GRC policies, control frameworks, risk scoring models, Security incident workflows, and Vulnerability Response processes; ensure designs are documented, peer-reviewed, and aligned with enterprise security and compliance standards.
  • Serve as the primary technical authority for the ServiceNow Risk & Security product, govern configuration standards, assess the technical impact of platform upgrades and patch releases, and maintain configuration documentation, technical debt register entries, and architectural decision records.
  • Drive operational readiness using a delivery readiness checklist covering support model requirements, training needs, continuity planning, configuration and runbook documentation, release notes, and user onboarding.
  • Define and maintain the Product performance dashboard, tracking adoption, cycle time and throughput, stability and defects, user-experience signals such as CSAT, SUS, and completion rates, and support effort; use performance insights to drive continuous improvement.
  • Ensure product changes follow required security controls, risk assessments, data handling policies, and regulated change processes, obtaining approvals from relevant subject-matter experts where required.
  • Support Solution Architects in assessing design options and managing cross-Product dependencies, contract and interface impacts, and sequencing needs to support interoperability and consistent business outcomes.
  • Act as an escalation point for the Product team and business users on functional product issues, guiding decisions within agreed financial, risk, and architectural guardrails.
  • Improve delivery practices within the Product by promoting agile approaches such as SAFe and Scrum, iterative and value-driven delivery, data-led ways of working, and meaningful measurement of benefits and operational impact.
Desired Qualifications
  • Industry certifications such as Agile Methodologies or CPM.
  • Hands-on expertise configuring and delivering ServiceNow Risk & Security modules, including Integrated Risk Management, GRC, Security Operations, and Vulnerability Response capabilities in complex environments.
  • Strong understanding of ServiceNow CMDB and data models, including designing solutions aligned with CMDB and CSDM structures to keep risk, vulnerability, and service data consistent across modules.
  • A track record in technical product ownership with MSP delivery partnerships, including leading technical backlogs and solution design while coordinating implementation through managed service providers and third-party teams.
  • A risk, security, and compliance mindset, including working with Risk, Security, and Compliance stakeholders to embed controls, support SLA-driven vulnerability management, and align configurations with enterprise standards.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Associated Press
Oct 21st, 2026
FDA approves GSK's Hibsago, offering 19% functional cure rate for chronic hepatitis B

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

The Reporter
Oct 15th, 2026
Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco.

Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco. Company is currently in tax dispute with local district, township. PUBLISHED: October 15, 2026 at 1:32 PM EDT UPDATED: October 15, 2026 at 1:38 PM EDT UPPER GWYNEDD - Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development Secretary Rick Siger announced on Wednesday that the state has secured a $2.9 billion investment from Merck global biopharmaceutical company to expand its operations in Montgomery County by the end of 2030. Pennsylvania is investing $5 million in the company's expansion, which will support the manufacturing of lifesaving products and medicine discovery, according to a statement from Shapiro and Siger. As part of the $2.9 billion commitment, Merck is investing $550 million in ADVANCE, a state-of-the-art robotics and AI-enabled drug research and development facility at its West Point Campus, and the nearby Springhouse Innovation Park R&D facility, which will help the company produce life-saving medicines. "My administration has made life sciences a key part of our economic development strategy here in Pennsylvania, and Merck's major investment in Montgomery County is another major win for the commonwealth," said Shapiro in a statement from his office. "We are proud to partner with Merck as they expand their operations in Montgomery County, advance cutting-edge research and manufacturing, and create new opportunities for thousands of Pennsylvanians. The life sciences industry is booming in Pennsylvania and I am committed to winning more investments like this and making sure our commonwealth remains a national leader in innovation, medicine, and manufacturing." A week earlier, also in Montgomery County, Shapiro and Siger announced that pharma giant GSK will invest more than $800 million to expand its facilities in King of Prussia, establishing a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development and advanced digital capabilities in a single site. Funding from RCAP. Merck received a funding proposal from DCED for a $5 million Redevelopment Assistance Capital Program grant for the first West Point projects. Shapiro and Siger were at Merck's West Point campus Wednesday to help cut the ribbon on the ADVANCE facility. West Point plays a critical role in global public health, manufacturing over 200 million doses of vaccines a year. "Merck's continued investment in Montgomery County is a testament to Pennsylvania's strength as a global hub for life sciences, innovation, and advanced manufacturing," said Siger. "The commonwealth's $5 million RACP investment is helping support projects that will strengthen Merck's operations, advance the development and manufacturing of critical medicines and vaccines, and reinforce our competitive edge in an industry that is extremely important in Pennsylvania." In July, Upper Gwynedd Township officials announced that Merck was developing plans for a new manufacturing facility on their West Point campus, the most recent of several approved and built since the start of the 2020s, including expanding the existing "Building 45" for labs and office space in October 2020, a new "Building 50" of roughly 101,000 square feet of manufacturing space in February 2021, a new "Building 32" for freezer space approved in May 2021, expansion of the proposed "Building 50" in August 2021, and a new "Building 63A" production facility approved in November 2021. Merck also secured approvals in 2024 for a new "Building 41" toward the center of the company's 320-acre complex and in 2025 secured approvals from the township to swap preservation of wetlands on the site for another parcel elsewhere in the region. In September township officials approved the latest plans, for a vaccine manufacturing facility of roughly 75,000 square feet. The company, township, and North Penn School District have also been in a dispute over the firm's tax bill since early May, when Upper Gwynedd's staff asked that township's commissioners to approve a contract for new assessments of two properties township's comprising the West Point campus. In June the district hired a special counsel to handle the matter, and in September the school board created a new fund to keep Merck tax payments separate, saying the company was 'paying in protest' during the dispute. Joining Shapiro and Riger on Wedneday, Rob Davis, chairman and CEO of Merck, said, "The ADVANCE facility represents the future of clinical development at Merck and underscores our continued commitment to addressing the needs of the patients we serve." "This builds on our longstanding presence in Pennsylvania where we're proud to invest in the people, communities and scientific capabilities that will help drive the next generation of medicines," he said.

Seeking Alpha
Oct 14th, 2026
GSK plans more than 1,200 job cuts in Belgium.

GSK plans more than 1,200 job cuts in Belgium. GSK (GSK) plans to cut up to 1,217 jobs in Belgium as part of a proposed restructuring affecting research and development, production, and international support services, according to multiple Belgian media reports. The plan covers 482 white-collar employees and 735 management positions, according to union ABVV Chemie. Production-floor worker positions are reportedly excluded from the proposed reorganization. GSK (GSK) outlined the restructuring at a special works council meeting on Wednesday, October 14. The proposed changes affect GSK Biologicals, the group's vaccine business, according to a local report. GSK (GSK) employs about 8,500 people across its Belgian sites in Wavre, Rixensart and Gembloux. The proposed cuts follow a reduction of more than 400 jobs in Belgium during 2025, mainly through temporary-contract non-renewals and voluntary departure. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.